Business
Aurora Spine Corporation Announces Record First Quarter Financial Results
- Company to host conference call Today, Thursday, May 22 nd at 11am ET/8am PT - ...
About this update from Aurora Spine Corp.
[{"type":"text","content":"Aurora Spine Corporation Announces Record First Quarter Financial Results\n\n\n\n\n - Company to host conference call Today, Thursday, May 22\n \n\n\n nd\n \n\n\n at 11am ET/8am PT -\n \n\n\n\n NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES\n \n\n\n CARLSBAD, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves spinal surgery outcomes, today announced its financial results for first quarter ended March 31, 2025.\n \n\n All figures are in U.S. dollars.\n \n\n\n Financial and Business Highlights\n \n\n\n\n\n FDA Clearance for AERO\n \n ™ - the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the Company’s newest product, the AERO™ Facet Fusion System.\n \n\n\n\n\n Record Q1 revenue –\n \n The company reported a record level of revenues for its first quarter. Q1 2025 sales of $4,417,027 represent an increase of $403,226 or 10.0% compared to sales of $4,013,801 in the same period the previous year.\n \n\n\n\n\n Patient Studies\n \n – The Company has closed data collection in its REFINE study of its ZIP™ Interspinous Fixation device for patients suffering from back pain due to symptomatic degenerative disc disease. Data from the study will be published out to one year, with a subsequent cohort publication extending to two years, offering long-term insights into patient outcomes. An abstract will be presented at the American Society of Pain and Neuroscience (ASPN) annual conference in July 2025, spotlighting Aurora Spine’s commitment to evidence-based innovation.\n \n\n\n\n\n DEXA-C increased sales –\n \n The Company renewed its focus on the cervical spine market in Q1 2025 with $415K in cervical sales. This is a $204K increase over Q1 2024 and a $112K increase over Q4 2025. The majority of the increase is due to sales of the DEXA-C cervical implant.\n \n\n\n\n\n Spine Sales –\n \n Spine sales have stabilized with the hiring of a spine focused sales director representing $1.03 million in sales in Q1 2025, as compared to $867K in Q1 2024 and $902K in Q4 2024. The Company expects that the continued focus will expand spine sales in 2025, especially DEXA-C ce...